United States - English - NLM (National Library of Medicine)

physicians total care, inc. - didanosine (unii: k3gdh6oh08) (didanosine - unii:k3gdh6oh08) - didanosine 250 mg - didanosine delayed-release capsules, also known as ddi, in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus (hiv)-1 infection [see clinical studies (14) ]. these recommendations are based on either drug interaction studies or observed clinical toxicities. coadministration of didanosine and allopurinol is contraindicated because systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity [see clinical pharmacology (12.3) ]. coadministration of didanosine and ribavirin is contraindicated because exposures of the active metabolite of didanosine (dideoxyadenosine 5’-triphosphate) are increased. fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin. pregnancy category b reproduction studies have been performed in rats and rabbits at doses up to 12 and 14.2 times the estimated human exp

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - didanosine (unii: k3gdh6oh08) (didanosine - unii:k3gdh6oh08) - didanosine 125 mg - didanosine delayed-release capsules, also known as ddi, in combination with other antiretroviral agents are indicated for the treatment of human immunodeficiency virus (hiv)-1 infection [see clinical studies (14) ] . didanosine delayed-release capsules are contraindicated when coadministered with the following medications: - stavudine- potential for serious and/or life-threatening events, notably pancreatitis, lactic acidosis, hepatotoxicity, and peripheral neuropathy [see warnings and precautions (5.1, 5.2, 5.3, 5.5)] . - allopurinol- systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity [see clinical pharmacology (12.3) ]. - ribavirin- exposures of the active metabolite of didanosine (dideoxyadenosine 5′-triphosphate) are increased. fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin. pregnancy exposure registry there is a preg

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - didanosine (unii: k3gdh6oh08) (didanosine - unii:k3gdh6oh08) - didanosine 250 mg - didanosine delayed-release capsules, also known as ddi, in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus (hiv)-1 infection [see clinical studies (14) ]. these recommendations are based on either drug interaction studies or observed clinical toxicities. coadministration of didanosine and allopurinol is contraindicated because systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity [see clinical pharmacology (12.3) ]. coadministration of didanosine and ribavirin is contraindicated because exposures of the active metabolite of didanosine (dideoxyadenosine 5’-triphosphate) are increased. fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin. pregnancy category b reproduction studies have been performed in rats and rabbits at doses up to 12 and 14.2 times the estimated human exp

United States - English - NLM (National Library of Medicine)

bristol-myers squibb company - didanosine (unii: k3gdh6oh08) (didanosine - unii:k3gdh6oh08) - didanosine 125 mg - videx® ec (didanosine, usp), also known as ddi, in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus (hiv)-1 infection [see clinical studies (14) ]. videx ec is contraindicated when coadministered with the following medications: - stavudine- potential for serious and/or life-threatening events, notably pancreatitis, lactic acidosis, hepatotoxicity, and peripheral neuropathy [see warnings and precautions (5.1, 5.2, 5.3, 5.5) ]. - allopurinol- systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity [see clinical pharmacology (12.3) ]. - ribavirin- exposures of the active metabolite of didanosine (dideoxyadenosine 5′-triphosphate) are increased. fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin. there is a pregnancy exposure registry that monitors pregnancy outcomes in indivi

United States - English - NLM (National Library of Medicine)

bristol-myers squibb company - didanosine (unii: k3gdh6oh08) (didanosine - unii:k3gdh6oh08) - didanosine 10 mg in 1 ml - videx® (didanosine, usp), also known as ddi, in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus (hiv)-1 infection [see clinical studies (14) ]. videx is contraindicated when coadministered with the following medications: - stavudine- potential for serious and/or life-threatening events notably pancreatitis, lactic acidosis, hepatotoxicity, and peripheral neuropathy [see warnings and precautions (5.1, 5.2, 5.3, 5.5)]. - allopurinol- systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity [see clinical pharmacology (12.3) ]. - ribavirin- exposures of the active metabolite of didanosine (dideoxyadenosine 5′-triphosphate) are increased. fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin. there is a pregnancy exposure registry that monitors pregnancy outcomes in individ

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - didanosine (unii: k3gdh6oh08) (didanosine - unii:k3gdh6oh08) - didanosine 200 mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - didanosine -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - didanosine -

Ireland - English - HPRA (Health Products Regulatory Authority)

bristol-myers squibb pharmaceuticals uc - didanosine - gastro-resistant capsule - 200 milligram(s) - nucleoside and nucleotide reverse transcriptase inhibitors; didanosine

Ireland - English - HPRA (Health Products Regulatory Authority)

bristol-myers squibb pharmaceuticals uc - didanosine - gastro-resistant capsule - 250 milligram(s) - nucleoside and nucleotide reverse transcriptase inhibitors; didanosine